- Home
- OXSQ vs HURA Comparison
OXSQ vs HURA Comparison
Compare OXSQ & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXSQ
- HURA
- Stock Information
- Founded
- OXSQ 2003
- HURA 2009
- Country
- OXSQ United States
- HURA United States
- Employees
- OXSQ N/A
- HURA N/A
- Industry
- OXSQ Blank Checks
- HURA
- Sector
- OXSQ Finance
- HURA
- Exchange
- OXSQ Nasdaq
- HURA Nasdaq
- Market Cap
- OXSQ 144.4M
- HURA 131.8M
- IPO Year
- OXSQ N/A
- HURA N/A
- Fundamental
- Price
- OXSQ $1.92
- HURA $2.51
- Analyst Decision
- OXSQ
- HURA Strong Buy
- Analyst Count
- OXSQ 0
- HURA 2
- Target Price
- OXSQ N/A
- HURA $11.50
- AVG Volume (30 Days)
- OXSQ 757.9K
- HURA 178.6K
- Earning Date
- OXSQ 11-04-2025
- HURA 11-14-2025
- Dividend Yield
- OXSQ 21.99%
- HURA N/A
- EPS Growth
- OXSQ N/A
- HURA N/A
- EPS
- OXSQ N/A
- HURA N/A
- Revenue
- OXSQ $40,142,565.00
- HURA N/A
- Revenue This Year
- OXSQ N/A
- HURA N/A
- Revenue Next Year
- OXSQ $0.12
- HURA N/A
- P/E Ratio
- OXSQ N/A
- HURA N/A
- Revenue Growth
- OXSQ N/A
- HURA N/A
- 52 Week Low
- OXSQ $1.56
- HURA $1.80
- 52 Week High
- OXSQ $2.96
- HURA $7.20
- Technical
- Relative Strength Index (RSI)
- OXSQ 56.13
- HURA 51.26
- Support Level
- OXSQ $1.83
- HURA $2.40
- Resistance Level
- OXSQ $1.95
- HURA $2.58
- Average True Range (ATR)
- OXSQ 0.06
- HURA 0.11
- MACD
- OXSQ 0.02
- HURA 0.02
- Stochastic Oscillator
- OXSQ 85.42
- HURA 78.57
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.